DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for Glycogen Storage Disease Type 2b — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGlycogen Storage Disease Type 2b maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for glycogen storage disease type 2b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Sixty-three patients with glycogen storage disease were evaluated in a 1979 study using plain film, excretory urography, barium gastrointestinal studies, ultrasonography, and angiography. Type II disease displayed either cardiac or skeletal muscle glycogen deposition. No drug treatment was tested or mentioned in that study.
A 1995 paper on glycogen storage disease type 1b described oral complications in three children. Oral ulcers were a common finding, probably due to severe neutropenia and impaired neutrophil migration that characterise the onset of this rare disorder. No drug treatment was tested or mentioned in that paper.
A 2023 study investigated the chemical stability of marketed oral ribavirin syrup under accelerated conditions at 40°C and 75% relative humidity for six months. The ribavirin content changed throughout the storage period. The syrup remained physically stable but its chemical stability was affected. This study did not involve patients with glycogen storage disease type 2b, did not test ribavirin against that disease, and reported no clinical outcomes.
No abstract provided here tests any drug in patients with glycogen storage disease type 2b. What is missing is any clinical trial of a repurposed drug in that specific patient population, any evidence of a biological rationale linking a candidate drug to the disease mechanism, and any funding or trial design that would allow such a study to be conducted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Roentgenology · 1979 · 33 citations
Radiography of glycogen storage diseases
AbstractSixty-three patients with glycogen storage disease were evaluated. Findings on plain film examinations, excretory urography, barium gastrointestinal studies, ultrasonography, and angiography were categorized by type of glycogen storage disease. In type I findings include hepatomegaly with hepatic dysfunction, renomegaly with an increased incidence of renal calculi, and osteopenia with various associated osseous abnormalities. These changes were less pronounced in types III, IV, and VI. Type II displayed either cardiac or skeletal muscle glycogen deposition. Correlation with postmortem examination in 14 individuals is given.
Journal of Oral Pathology and Medicine · 1995 · 17 citations
Oral manifestations in glycogen storage disease type 1b
AbstractGlycogen storage disease type 1b is a rare metabolic disorder which affects the transport system of glucose-6-phosphatase metabolism. As a result, hepatomegaly, failure to thrive, renal dysfunction and recurrent infections occur in affected patients. In this paper, the oral complications in three children with glycogen storage disease type 1b are discussed. Oral ulcers were a common finding, probably due to severe neutropenia and impaired neutrophil migration which characterises the onset of this rare disorder.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
STABILITY STUDIES OF RIBAVIRIN SYRUP
AbstractRibavirin is an antiviral agent commonly used for the treatment of severe acute respiratory<br> syndrome. The present study investigated the stability of marketed oral Ribavirin syrup. The<br> syrup was subjected to accelerated stability testing at 40°C and 75% RH for 6 months as per<br> ICH guidelines. HPLC method to estimate Ribavirin was developed and validated.<br> Employing a validated high-performance liquid chromatographic method, the Ribavirin<br> content of the syrup has been demonstrated to exhibit changes throughout the storage period.<br> No physical changes was observed in syrup suggesting that it remained physically stable, but<br> effected the chemically stability of syrup under the stated conditions.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
